181 related articles for article (PubMed ID: 12618491)
1. Is tamoxifen the Rosetta stone for breast cancer?
Jordan VC
J Natl Cancer Inst; 2003 Mar; 95(5):338-40. PubMed ID: 12618491
[No Abstract] [Full Text] [Related]
2. Hormones 'R' us.
Sledge GW
Clin Breast Cancer; 2002 Jan; 2(4):251. PubMed ID: 11899355
[No Abstract] [Full Text] [Related]
3. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
4. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Wu K; Brown P
J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
[No Abstract] [Full Text] [Related]
5. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM; Jackson J; Renshaw L; Miller WR
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
[TBL] [Abstract][Full Text] [Related]
6. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors continue their ATAC on tamoxifen.
Nicholls H
Trends Mol Med; 2002; 8(4 Suppl):S12-3. PubMed ID: 11927281
[No Abstract] [Full Text] [Related]
8. Tamoxifen: Dr. Jekyll and Mr. Hyde?
Hayes DF
J Natl Cancer Inst; 2004 Jun; 96(12):895-7. PubMed ID: 15199102
[No Abstract] [Full Text] [Related]
9. [Anastrozolo: intracellular anti-aromatase activity and pharmacologic interactions. Satellite Symposium AIOM 1999 - Roma].
Longo F; Mansueto G
Tumori; 1999; 85(6):A19-25. PubMed ID: 10774583
[No Abstract] [Full Text] [Related]
10. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
11. ERBB2 status and outcome of endocrine treatment.
Miller WR
Lancet Oncol; 2008 Jan; 9(1):4-5. PubMed ID: 18177812
[No Abstract] [Full Text] [Related]
12. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
13. Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Twombly R
J Natl Cancer Inst; 2003 Dec; 95(23):1738-9. PubMed ID: 14652229
[No Abstract] [Full Text] [Related]
14. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
15. The secrets of selective estrogen receptor modulation: cell-specific coregulation.
Jordan VC
Cancer Cell; 2002 Apr; 1(3):215-7. PubMed ID: 12086856
[TBL] [Abstract][Full Text] [Related]
16. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
17. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
[TBL] [Abstract][Full Text] [Related]
18. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Bergmann L
Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
[No Abstract] [Full Text] [Related]
19. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
20. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
